Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Return on Assets for 10 consecutive years, with 0.41% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Assets fell 33.0% to 0.41% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.41%, a 33.0% decrease, with the full-year FY2025 number at 0.36%, down 15.0% from a year prior.
  • Return on Assets was 0.41% for Q4 2025 at Cartesian Therapeutics, down from 0.22% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.15% in Q3 2022 to a low of 0.41% in Q4 2025.
  • A 5-year average of 0.14% and a median of 0.14% in 2021 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: skyrocketed 59bps in 2021, then plummeted -51bps in 2023.
  • Cartesian Therapeutics' Return on Assets stood at 0.08% in 2021, then soared by 247bps to 0.12% in 2022, then tumbled by -418bps to 0.39% in 2023, then soared by 79bps to 0.08% in 2024, then plummeted by -399bps to 0.41% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Return on Assets are 0.41% (Q4 2025), 0.22% (Q3 2025), and 0.2% (Q2 2025).